Paediatrics Publications
Survival Following Tumor Recurrence in Children With Medulloblastoma
Document Type
Article
Publication Date
4-2018
Journal
Journal of Pediatric Hematology/Oncology
Volume
40
Issue
3
First Page
159
Last Page
159
URL with Digital Object Identifier
https://doi.org/10.1097/MPH.0000000000001095
Abstract
Medulloblastoma is the most common malignant brain tumor in children. Published survival rates for this tumor are ∼70%; however, there is limited published information on outcome after disease recurrence. This was an observational study which included all persons under the age of 18 years diagnosed with medulloblastoma from 1990 to 2009 inclusive in Canada. Data collected included date of diagnosis, age at diagnosis, sex, stage, pathology, treatment, recurrence, and current status. Survival rates were determined. In total, 550 cases were ascertained meeting the study criteria. The overall survival rate at 1 year was 83.6%±1.7%, at 3 years 77.2%±1.9%, and at 5 years 72.5%±20%. The progression-free survival rates were 78%±1.9%, 70%±2.1%, and 69±2.1% at 1, 3, and 5 years from initial diagnosis. In total, 173 (31.2%) were reported to have had tumor recurrence and 23 (11.4%) of them were alive at the time of survey with an overall survival rate at 1 year of 38.3%±4%, at 2 years of 16.9%±3.3%, and at 5 years of 12.4%±2.8%. Our data confirm that children with recurrent medulloblastoma have a poor prognosis, supporting the need for novel treatment approaches for this group.
Notes
Article available at Journal of Pediatric Hematology/Oncology, Vol. 40(3).
https://doi.org/10.1097/MPH.0000000000001095
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.